Zymergen Inc. (ZY): Price and Financial Metrics
ZY Price/Volume Stats
|Current price||$2.43||52-week high||$12.42|
|Prev. close||$2.39||52-week low||$1.10|
|Day high||$2.59||Avg. volume||1,229,575|
|50-day MA||$2.65||Dividend yield||N/A|
|200-day MA||$2.77||Market Cap||253.58M|
ZY Stock Price Chart Interactive Chart >
Zymergen Inc. (ZY) Company Bio
Zymergen Inc. designs, engineers, and optimizes microbes for industrial applications in United States, Asia, and Europe. The company has a platform that treats the genome as a search space, to identify genetic changes that improve the economics for its customers' bio-based products for a range of industries, including chemicals and materials, agriculture, and pharmaceuticals. Zymergen's platform is used to discover novel molecules used to enable unique material properties. The company was incorporated in 2013 and is based in Emeryville, California.
ZY Latest News Stream
|Loading, please wait...|
ZY Latest Social Stream
View Full ZY Social Stream
Latest ZY News From Around the Web
Below are the latest news stories about ZYMERGEN INC that investors may wish to consider to help them evaluate ZY as an investment opportunity.
By Yasin Ebrahim
Beaten down from its highs late last year, cell engineering company Ginkgo Bioworks now looks primed to divide and conquer.
The synthetic biology leader's healthy cash balance provides plenty of breathing room, but it won't last forever.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) agreed to acquire Zymergen Inc (NASDAQ: ZY) in an all-stock transaction. Zymergen stockholders will receive 0.9179 shares of Ginkgo's Class A common stock for each Zymergen share. The deal values Zymergen at approximately $300 million and would provide Zymergen shareholders about 5.25% pro forma ownership of Ginkgo. Ginkgo plans to integrate Zymergen's core automation and software technologies for scaling strain engineering capacity into its foundry, incl
Today, Ginkgo Bioworks (NYSE: DNA) — the leading horizontal platform for cell programming — and the biotechnology company Zymergen (Nasdaq: ZY) announced they have entered into a definitive agreement under which Ginkgo will acquire Zymergen in an all-stock transaction that values Zymergen at an approximately $300 million market capitalization. Under the terms of the agreement, which have been unanimously approved by the boards of directors of both companies, Zymergen stockholders will receive a
ZY Price Returns